Investor Presentation First Nine Months of 2023
72
Investor presentation
First nine months of 2023
Novo NordiskⓇ
In a 20-week phase 1 trial, CagriSema showed weight loss of 17%
and appeared to have a safe and well tolerated profile
Weight loss for different doses of CagriSema in phase 1
The GI profile appeared similar to semaglutide 2.4 monotherapy
Change in
body weight
0
-5
-10
Last dosing
n=12 n=12 n=12
n=12 n=12 n=11 n=24
N (%) N (%)
N (%)
N (%) N (%)
N (%)
N (%)
AES
11 (92) 12 (100) 11 (92) 12 (100) 12 (100) 11 (100) 23 (96)
SAES1
0
0
0
1(8)
0
0
0
AEs leading to
withdrawal
1 (8)
0
0
1 (8)
0
0
0
-15
GI disorders
7 (58) 10 (83) 7 (58) 10 (83) 11 (92) 9 (82) 19 (79)
0
14
28 42 56 70 84 98 112 126 140
Time since first dosing (days)
Follow-up
Cagri 0.16 mg,
Cagri 0.3 mg,
Sema 2.4 mg
Sema 2.4 mg
Cagri 0.6 mg,
Sema 2.4 mg
Cagri 1.2 mg,
Sema 2.4 mg
Cagri 2.4 mg,
Sema 2.4 mg
Cagri 4.5 mg,
Sema 2.4 mg
✗ Placebo,
Sema 2.4 mg
1 The serious adverse event was meningitis
CagriSema: Cagrilintide in combination with semaglutide; Cagri: Cagrilintide; Sema: semaglutide; SAE: Serious adverse events; GI: Gastro-intestinal; Change in body weight is analysed using a mixed model for repeated measurements, where all changes from
baseline in body weight measurements enter as the dependent variables and treatment, visit and baseline body weight enter as fixed effects. Treatment and baseline body weight are nested within visit.
Source: Adapted from Enebo et al. Lancet. 2021 May 8;397(10286):1736-1748.View entire presentation